Polaryx Therapeutics, Inc. (PLYX)
NASDAQ: PLYX · Real-Time Price · USD
3.520
+0.780 (28.47%)
At close: Mar 9, 2026, 4:00 PM EDT
3.290
-0.230 (-6.53%)
Pre-market: Mar 10, 2026, 4:03 AM EDT
Company Description
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders.
Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
The company was founded in 2014 and is based in Paramus, New Jersey.
Polaryx Therapeutics, Inc.
| Country | United States |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Alex Yang |
Contact Details
Address: South Tower, 140 E Ridgewood Avenue Paramus, New Jersey 07652 United States | |
| Phone | 201 940 7236 |
| Website | polaryx.com |
Stock Details
| Ticker Symbol | PLYX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002075320 |
| CUSIP Number | 73110F100 |
| ISIN Number | US73110F1003 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alex Yang J.D., L.L.M. | Chief Executive Officer and Chair of Board |
| G. Michael Landis CPA | Chief Financial Officer and Director |
| Andrew John O | Chief Investment Officer |
| Dr. Lisa L. Bollinger M.D. | Chief Medical Officer |
| Dr. Shrijay Vijayan M.B.A., Ph.D. | Chief Scientific and Business Development Officer |
| Wuxin Zhu P.M.P., Ph.D. | Chief Chemistry, Manufacturing and Controls Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 5, 2026 | SCHEDULE 13D | Filing |
| Feb 2, 2026 | 424B4 | Prospectus |
| Jan 29, 2026 | EFFECT | Notice of Effectiveness |
| Jan 28, 2026 | CERT | Certification by an exchange approving securities for listing |
| Jan 27, 2026 | 8-A12B | Registration of securities |
| Jan 27, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 14, 2026 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Nov 21, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Oct 31, 2025 | C-U | Filing |
| Oct 27, 2025 | C-U | Filing |